L
Lionel Rostaing
Researcher at University of Grenoble
Publications - 638
Citations - 27270
Lionel Rostaing is an academic researcher from University of Grenoble. The author has contributed to research in topics: Transplantation & Kidney transplantation. The author has an hindex of 81, co-authored 598 publications receiving 24252 citations. Previous affiliations of Lionel Rostaing include French Institute of Health and Medical Research & Centre Hospitalier Universitaire de Toulouse.
Papers
More filters
Journal ArticleDOI
Hepatitis E virus and chronic hepatitis in organ-transplant recipients.
Nassim Kamar,Janick Selves,Jean-Michel Mansuy,Leila Ouezzani,Jean-Marie Péron,Joelle Guitard,Olivier Cointault,Laure Esposito,Florence Abravanel,Marie Danjoux,Dominique Durand,Jean-Pierre Vinel,Jacques Izopet,Lionel Rostaing +13 more
TL;DR: The time from transplantation to diagnosis was significantly shorter and the total counts of lymphocytes and of CD2, CD3, and CD4 T cells were significantly lower in patients in whom chronic disease developed.
Journal ArticleDOI
A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study).
Flavio Vincenti,Bernard Charpentier,Yves Vanrenterghem,Lionel Rostaing,Barbara A. Bresnahan,P. Darji,Pablo U. Massari,G. A. Mondragón‐Ramirez,M. Agarwal,G. Di Russo,C.-S. Lin,P. Garg,Christian P. Larsen +12 more
TL;DR: Belatacept was associated with superior renal function and similar patient/graft survival versus cyclosporine at 1 year posttransplant, despite a higher rate of early acute rejection.
Journal ArticleDOI
Genetics and Outcome of Atypical Hemolytic Uremic Syndrome: A Nationwide French Series Comparing Children and Adults
Véronique Frémeaux-Bacchi,Fadi Fakhouri,Arnaud Garnier,Frank Bienaimé,Marie-Agnès Dragon-Durey,Stéphanie Ngo,Bruno Moulin,Aude Servais,François Provôt,Lionel Rostaing,Stéphane Burtey,Patrick Niaudet,Georges Deschênes,Yvon Lebranchu,Julien Zuber,Chantal Loirat +15 more
TL;DR: Mortality rate was higher in children than adults with aHUS, but renal prognosis was worse in adults than children, and in children, the prognosis strongly depends on the genetic background.
Journal ArticleDOI
Belatacept and Long-Term Outcomes in Kidney Transplantation.
Flavio Vincenti,Lionel Rostaing,J. Grinyo,Kim Rice,Steven M. Steinberg,Luis Gaite,Marie-Christine Moal,Guillermo A. Mondragon-Ramirez,Jatin Kothari,Martin Polinsky,Herwig Ulf Meier-Kriesche,Stephane Munier,Christian P. Larsen +12 more
TL;DR: Seven years after transplantation, patient and graft survival and the mean eGFR were significantly higher with belatacept (both the more-intensive and the less-intensive regimen) than with cyclosporine, and a 43% reduction in the risk of death or graft loss was observed.
Journal ArticleDOI
Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus.
Flavio Vincenti,Styrbjörn Friman,E. H. Scheuermann,Lionel Rostaing,Trond Jenssen,Josep M. Campistol,K. Uchida,Mark D. Pescovitz,Piero Marchetti,Murat Tuncer,Franco Citterio,Andrzej Wiecek,Steven J. Chadban,M. El‐Shahawy,Klemens Budde,N. Goto +15 more
TL;DR: The incidence of NODAT or IFG at 6 months post‐transplant is significantly lower with CsA‐ME than with tacrolimus without a significant difference in short‐term outcome, and the profile and incidence of adverse events were similar between treatments.